ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Bristol-Myers Squibb CEO insists proposed Celgene purchase not a "defensive deal" firstwordpharma
March 13, 2019Bristol-Myers Squibb CEO Giovanni Caforio reiterated that the company's proposed?$74-billion acquisition?of Celgene is not designed to fend-off a takeover of the company. This "is not [a] defensive deal," Caforio said, as the drugmaker looks to persuade i
Pharma Sources Insight January 2025
